#4 - Moderna (NASDAQ:MRNA)
Moderna Inc. (NASDAQ: MRNA) became a household name in 2020 and 2021 when it was one of the biotechnology companies approved for a COVID-19 vaccine.
Its vaccine, developed alongside Pfizer Inc. (NYSE: PFE), was significant for using mRNA technology—a new approach that teaches the body’s cells to produce proteins that trigger an immune response. This method allows for faster, more adaptable vaccine development.
Moderna’s broader mission is to transform medicine by making mRNA-based treatments a reality. Beyond vaccines, the company is now exploring mRNA’s potential in treating cancer—in partnership with Merck & Co. (NYSE: MRK)—as well as genetic disorders and other unmet medical needs.
However, the real game-changer may come as mRNA medicines are used to develop potential new treatments for cancer, in partnership with Merck & Co. (NYSE: MRK), as well as genetic disorders and other unmet health conditions. At the beginning of 2025, Moderna forecasted 10 new drug approvals in the next three years.
About Moderna
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
More about Moderna- Current Price
- $24.40
- Consensus Rating
- Hold
- Ratings Breakdown
- 4 Buy Ratings, 15 Hold Ratings, 4 Sell Ratings.
- Consensus Price Target
- $53.95 (121.1% Upside)
